



Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019. Dr. Gottlieb's work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. He is currently a senior fellow at the American Enterprise Institute and a member of the board of directors of Pfizer, Inc, Illumina Inc, and Tempus Labs. Dr. Gottlieb is a partner at the venture capital firm New Enterprise Associates where he is a member of the firm's healthcare services and biopharma investment teams. For NEA, he serves on the boards of National Resilience and Action.

Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The agency advanced new models for the regulation of artificial intelligence devices, veterinary medicines, and orphan drugs; and implemented new reforms to standardize drug reviews and make important improvements in post market data collection and the use of real-world evidence. The agency's historic and prolific advances in new policy distinguished his tenure as the FDA's commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines in 2018 and again in 2019.

Dr. Gottlieb promoted policies to reduce death and disease from tobacco, improve food innovation and safety, expand the agency's oversight of areas of emerging risk such as dietary supplements and cell-based medicine, and aggressively confront addiction crises. The FDA advanced new legislative frameworks to address the opioid crisis, grow its field operations, and modernize the regulation of diagnostic tests and over-the-counter drugs, among other initiatives. Dr. Gottlieb forged collaborative relations with Congress that saw FDA increase its total budget by about \$1 billion over two years. During his tenure, he testified before Congress 20 times.

Previously, Dr. Gottlieb served as the FDA's Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped implement the Medicare drug benefit, and advance policies to improve healthcare quality and promote the effective use of new medical technologies.

Dr. Gottlieb is author of the New York Times bestselling book "Uncontrolled Spread" and is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He holds an editorial position on the Journal of the American Medical Association. Fortune Magazine recognized him as one of the "World's 50 Greatest Leaders" in 2018 and again in 2019. Modern Healthcare has named Dr. Gottlieb as one of the "Most Influential Physician Executive and Leaders" in its annual survey of 50 physician executives, and Time magazine named Dr. Gottlieb as one of its "50 People Transforming Healthcare in 2018." He is a contributor to CNBC and CBS News Face the Nation.

Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. He is an elected member of the National Academy of Medicine.